Synlogic, Inc. (NASDAQ:SYBX) Short Interest Update

Synlogic, Inc. (NASDAQ:SYBX) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 9,485 shares, a decrease of 38.5% from the November 30th total of 15,427 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 98,523 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 98,523 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are short sold.

Institutional Investors Weigh In On Synlogic

An institutional investor recently bought a new position in Synlogic stock. Citadel Advisors LLC acquired a new stake in Synlogic, Inc. (NASDAQ:SYBX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 29,011 shares of the biotechnology company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 0.25% of Synlogic at the end of the most recent quarter. 63.40% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Synlogic in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Synlogic Price Performance

Shares of SYBX opened at $1.22 on Friday. Synlogic has a 1-year low of $0.90 and a 1-year high of $1.96. The stock has a market cap of $14.27 million, a PE ratio of -4.69 and a beta of 0.36. The firm has a fifty day moving average price of $1.46 and a 200 day moving average price of $1.47.

Synlogic (NASDAQ:SYBX) last posted its earnings results on Thursday, November 13th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.08). As a group, equities analysts expect that Synlogic will post -2.71 EPS for the current fiscal year.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.